Homepage
Catalog of Screening Compounds
Screening Libraries
Focused and Target Libraries
Active Reference Sets
Diversity Libraries
Screening Compounds
Building blocks
Drug Discovery Services
Custom Chemistry
Medicinal chemistry
In silico Drug Design (CADD)
Discovery Biology
Animal Models
Toxicology and Safety
ADME, DMPK
Chemistry, Manufacturing and Controls
Company
News & Media
Contact us
For suppliers
Trends in discovery compounds
Homepage
>
Company
>
Media
>
Pharma News
>
2025
Pharma News, 2025
J&J for Cancer Treatment Costs
US Could Seek More Than $1B From J&J for Cancer Treatment Costs
PVRI Congress
Gossamer Bio showcases seralutinib seralutinib Clinical and Preclinical studies at PVRI Congress
Rentschler closes UK
Rentschler closes UK cell and gene therapy facility and does a pivot to biologics
NIH-supported clinical
NIH-supported clinical trial to test experimental treatment for dengue
FDA approves Vertex’s
FDA approves Vertex’s acute pain treatment Journavx
New research unlocks
New research unlocks key to long-lasting immune response in cancer and chronic diseases
Fitusiran
Fitusiran Is a Drug to Watch in the Hematology Space in 2025
FDA approves
FDA approves drug application for Lupin’s heart failure therapy
Merck, Eisai's
Merck, Eisai's star-crossed Keytruda-Lenvima combo misses survival goal in GI cancer trial
Emcure Pharmaceuticals
Emcure Pharmaceuticals opens new R&D centre in Gujarat, India
Ascentage Pharma
Ascentage Pharma raises $126m in first biotech IPO of 2025
Takeda bids adieu to Uloric
Takeda bids adieu to Uloric (febuxostat) after gout med's gradual fade from glory
46
47
48
49
50
51
52
53
54
